deferoxamine has been researched along with Vision, Diminished in 4 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report a case of acute bilateral central serous retinopathy associated with deferoxamine therapy in the context of paroxysmal nocturnal hemoglobinuria." | 7.83 | Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. ( Giasin, O; Kaneshyogan, H; Makrygiannis, G; Sian, IS; Vahdani, K, 2016) |
| "To report a case of acute bilateral central serous retinopathy associated with deferoxamine therapy in the context of paroxysmal nocturnal hemoglobinuria." | 3.83 | Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine. ( Giasin, O; Kaneshyogan, H; Makrygiannis, G; Sian, IS; Vahdani, K, 2016) |
| "Deferoxamine is a chelating agent used in the treatment of transfusional iron overload and more recently in the diagnosis and treatment of increased aluminum body stores in chronic renal failure patients." | 1.28 | Irreversible ocular toxicity from single "challenge" dose of deferoxamine. ( Bene, C; Bene, D; Kranias, G; Manzler, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Li, M | 1 |
| Diao, K | 1 |
| Wang, Y | 1 |
| Chen, H | 1 |
| Zhao, Z | 1 |
| Li, Y | 1 |
| Jia, X | 1 |
| Wang, H | 1 |
| Zheng, F | 1 |
| Xia, Z | 1 |
| Han, L | 1 |
| Zhang, M | 1 |
| Vahdani, K | 1 |
| Makrygiannis, G | 1 |
| Kaneshyogan, H | 1 |
| Sian, IS | 1 |
| Giasin, O | 1 |
| Reddy, S | 1 |
| Slakter, J | 1 |
| Aaberg, TM | 1 |
| Singh, RP | 1 |
| Kaiser, PK | 1 |
| Bene, C | 1 |
| Manzler, A | 1 |
| Bene, D | 1 |
| Kranias, G | 1 |
4 other studies available for deferoxamine and Vision, Diminished
| Article | Year |
|---|---|
Deferoxamine attenuates visual impairment in retinal ischemia‒reperfusion via inhibiting ferroptosis.
Topics: Animals; Deferoxamine; Ferritins; Ferroptosis; Glutathione; Humans; Rats; Reactive Oxygen Species; R | 2023 |
Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine.
Topics: Central Serous Chorioretinopathy; Deferoxamine; Fluorescein Angiography; Fundus Oculi; Hemoglobinuri | 2016 |
Diagnostic and therapeutic challenges.
Topics: Abdominal Pain; Aged; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Glomerulon | 2007 |
Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
Topics: Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Macular Edema; Middle Aged; Optic N | 1989 |